Suppr超能文献

确定初治转移性前列腺癌男性患者中临床医生评定的东部肿瘤协作组(ECOG)体能状态与患者报告的健康相关生活质量评分之间的关系。

Defining the relationship between clinician-rated ECOG performance status and patient-reported health-related quality of life scores in men with metastatic hormone-naïve prostate cancer.

作者信息

Nnabugwu Ikenna I, Obikeze Eric N, Nnabugwu Chinwe A, Anyimba Solomon K, Amu Okwudili C, Mbadiwe Okezie M, Echetabu Kevin S N, Okoronkwo Ijeoma L

机构信息

Urology Unit, Department of Surgery, Faculty of Medical Sciences, College of Medicine, University of Nigeria, Ituku-Ozalla Enugu, PMB 01129, Nigeria.

Department of Health Administration and Management, Faculty of Health Sciences and Technology College of Medicine, University of Nigeria Enugu Campus, Enugu, Nigeria.

出版信息

Health Qual Life Outcomes. 2024 Dec 24;22(1):111. doi: 10.1186/s12955-024-02318-y.

Abstract

BACKGROUND

Performance status and health-related quality of life (HRQoL) are important parameters in the management of metastatic prostate cancer. The clinician-rated Eastern Cooperative Oncology Group performance status (ECOG-PS) may not relate with the patient-reported HRQoL because the later puts into consideration some aspects of health that are not captured by the former. The aim of this study is to define the relationship between clinician-rated ECOG-PS and the patient-reported HRQoL in men with metastatic hormone-naïve prostate cancer (mPCa).

METHODS

An analytical cross-sectional study recruiting patients presenting with mPCa in Enugu, southeast Nigeria. Two clinicians agreed on an ECOG-PS score for each study participant who in turn completed the Functional Assessment in Cancer Therapy - Prostate (FACT-P) and the EuroQol EQ-5D-5 L questionnaires with interviewer-assistance where necessary. Other medical information was retrieved from the records. ANOVA and chi-square tests were used to compare available data across ECOG-PS ratings and ordinal logistic regression was used to determine the FACT-P questionnaire items that related significantly with the ECOG-PS scores.

RESULTS

Of the 224 participants (mean age: 70.62 ± 7.34), about 60.7% had ≥ 12years of formal education and 84.9% had ISUP grade ≥ 3 cancer. In all, 22.8%, 55.8%, 21.0% and 0.4% were ECOG-PS 1, ECOG-PS 2, ECOG-PS 3 and ECOG-PS 4 respectively. The mean FACT-P score, health utility index (HUI) and visual analogue scale (VAS) scores were 80.18 ± 17.56, 0.524 ± 0.324 and 60.43 ± 9.91% respectively. The FACT-P score (p = 0.002), HUI (p < 0.001) and VAS score (p < 0.001) varied significantly across the ECOG-PS ratings. Within the FACT-P, only questionnaire items GP3 (p = 0.024) and GP7 (p < 0.001) of the PWB domain, and items GF5 (p = 0.009) and GF6 (p = 0.003) of the FWB domain related strongly with the ECOG-PS categories.

CONCLUSION

There are indications that HRQoL questionnaire items that have to do with impairment in physical and role functioning relate strongly with ECOG-PS categories.

摘要

背景

体能状态和健康相关生活质量(HRQoL)是转移性前列腺癌管理中的重要参数。临床医生评定的东部肿瘤协作组体能状态(ECOG-PS)可能与患者报告的HRQoL无关,因为后者考虑了前者未涵盖的一些健康方面。本研究的目的是确定临床医生评定的ECOG-PS与转移性激素初治前列腺癌(mPCa)男性患者报告的HRQoL之间的关系。

方法

一项分析性横断面研究,在尼日利亚东南部埃努古招募患有mPCa的患者。两名临床医生就每位研究参与者的ECOG-PS评分达成一致,这些参与者依次完成癌症治疗功能评估-前列腺(FACT-P)和欧洲五维健康量表EQ-5D-5L问卷,必要时由访员协助。从记录中检索其他医学信息。使用方差分析和卡方检验比较ECOG-PS评级的可用数据,并使用有序逻辑回归确定与ECOG-PS评分显著相关的FACT-P问卷项目。

结果

在224名参与者中(平均年龄:70.62±7.34),约60.7%接受过≥12年正规教育,84.9%的ISUP分级≥3级癌症。总体而言,ECOG-PS 1、ECOG-PS 2、ECOG-PS 3和ECOG-PS 4分别占22.8%、55.8%、21.0%和0.4%。FACT-P评分、健康效用指数(HUI)和视觉模拟量表(VAS)评分的平均值分别为80.18±17.56、0.524±0.324和60.43±9.91%。FACT-P评分(p = 0.002)、HUI(p < 0.001)和VAS评分(p < 0.001)在ECOG-PS评级之间有显著差异。在FACT-P中,仅PWB领域的问卷项目GP3(p = 0.024)和GP7(p < 0.001)以及FWB领域的项目GF5(p = 0.009)和GF6(p = 0.003)与ECOG-PS类别密切相关。

结论

有迹象表明,与身体和角色功能受损相关的HRQoL问卷项目与ECOG-PS类别密切相关。

相似文献

4
A cross-sectional study evaluating health-related quality of life of Chinese pediatric patients with hematological malignancies using EQ-5D-Y.
Front Public Health. 2023 Jan 11;10:1050835. doi: 10.3389/fpubh.2022.1050835. eCollection 2022.
6
Health-Related Quality of Life Among Patients With HR+/HER2- Early Breast Cancer.
Clin Ther. 2021 Jul;43(7):1228-1244.e4. doi: 10.1016/j.clinthera.2021.04.020. Epub 2021 Jul 11.

本文引用的文献

1
Metastatic Hormone-Sensitive Prostate Cancer in the Era of Doublet and Triplet Therapy.
Curr Treat Options Oncol. 2024 Mar;25(3):293-312. doi: 10.1007/s11864-023-01173-1. Epub 2024 Jan 4.
6
Impact of COVID-19 pandemic on prostate cancer outcomes at an uro-oncology referral center.
Int Braz J Urol. 2023 Mar-Apr;49(2):233-242. doi: 10.1590/S1677-5538.IBJU.2022.0393.
7
Racial Disparities in Prostate Cancer Stage at Diagnosis Persist Despite Community Affluence.
Res Rep Urol. 2022 Aug 30;14:305-312. doi: 10.2147/RRU.S371838. eCollection 2022.
9
Treatments for Metastatic Hormone-sensitive Prostate Cancer: Systematic Review, Network Meta-analysis, and Benefit-harm assessment.
Eur Urol Oncol. 2022 Dec;5(6):605-616. doi: 10.1016/j.euo.2022.04.007. Epub 2022 May 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验